Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043256 | 0.76 | LMNA (0.61) | LMNACYP11B1CYP11B2FYNKLKB1 | |
| SCHEMBL7085127 | 0.73 | LMNA (0.61) | LMNASMN1; SMN2KMT2A | |
| SCHEMBL7081262 | 0.73 | BRAF (0.46) | LMNABRAFATR | |
| SCHEMBL7667672 | 0.70 | PIM2 (0.41) | BRAFCYP11B1CYP11B2 | |
| SCHEMBL12150535 | 0.69 | LMNA (0.62) | LMNAKMT2A | |
| SCHEMBL6480011 | 0.69 | LMNA (0.62) | LMNASMN1; SMN2KMT2A | |
| SCHEMBL6948039 | 0.68 | LMNA (0.53) | LMNAFYNTBXAS1KMT2A | |
| SCHEMBL5112 | 0.68 | L3MBTL1 (0.46) | CYP11B1CYP11B2CHEK1SMN1; SMN2KMT2A | |
| SCHEMBL9318665 | 0.67 | MEN1 (0.52) | LMNACYP11B1CYP11B2KLKB1KLK1 | |
| SCHEMBL7667133 | 0.67 | CYP19A1 (0.51) | LMNAFYNTBXAS1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | PAYNE LINDA S (US) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | CYP2S1, IMPDH1, IDO1 | LMNA 3637/4885BRAF 2358/4885CYP11B1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.